Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects

Seonghae Yoon1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Donghoon Shin1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Howard Lee1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea;2 Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea

In-Jin Jang1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Kyung-Sang Yu1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of KoreaCorrespondence[email protected]

Pages 5033-5049 | Published online: 31 Aug 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

RoddyEZhangWDohertyMIs gout associated with reduced quality of life? A case–control studyRheumatology20074691441144417586863
PubMed Web of Science ®Google Scholar
SinghJAStrandVGout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veteransAnn Rheum Dis20086791310131618178692
PubMed Web of Science ®Google Scholar
ChandratrePRoddyEClarsonLRichardsonJHiderSLMallenCDHealth-related quality of life in gout: a systematic reviewRheumatology201352112031204023934311
PubMed Web of Science ®Google Scholar
NeogiTClinical practice. GoutN Engl J Med2011364544345221288096
PubMed Web of Science ®Google Scholar
RoddyEChoiHKEpidemiology of goutRheum Dis Clin North Am201440215517524703341
PubMed Web of Science ®Google Scholar
LeeCHSungNYThe prevalence and features of Korean gout patients using the national health insurance corporation databaseJ Rheum Dis201118294100
Google Scholar
ShieldsGEBeardSMA systematic review of the economic and humanistic burden of goutPharmacoeconomics2015 Epub2015513
Google Scholar
WuEQForsytheAGuerinAYuAPLatremouille-ViauDTsanevaMComorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapyAm J Ther2012196e157e16621317625
PubMedGoogle Scholar
BrookRAKleinmanNLPatelPAThe economic burden of gout on an employed populationCurr Med Res Opin20062271381138916834837
PubMed Web of Science ®Google Scholar
WertheimerAMorlockRBeckerMAA revised estimate of the burden of illness of goutCurr Ther Res Clin Exp2013751424465034
PubMedGoogle Scholar
PluimHJvan DeurenMWetzelsJFThe allopurinol hypersensitivity syndromeNeth J Med19985231071109599967
PubMed Web of Science ®Google Scholar
LeeHYAriyasingheJTThirumoorthyTAllopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?Singapore Med J200849538438718465047
PubMed Web of Science ®Google Scholar
HandeKRNooneRMStoneWJSevere allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiencyAm J Med198476147566691361
PubMed Web of Science ®Google Scholar
Perez-RuizFCalabozoMFernandez-LopezMJTreatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled studyJ Clin Rheumatol199952495519078356
PubMed Web of Science ®Google Scholar
Vazquez-MelladoJMoralesEMPacheco-TenaCBurgos-VargasRRelation between adverse events associated with allopurinol and renal function in patients with goutAnn Rheum Dis2001601098198311557658
PubMed Web of Science ®Google Scholar
EdwardsNLTreatment-failure gout: a moving targetArthritis Rheum20085892587259018759307
PubMedGoogle Scholar
ChaoJTerkeltaubRA critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in goutCurr Rheumatol Rep200911213514019296886
PubMedGoogle Scholar
JacksonRLHuntBMacDonaldPAThe efficacy and safety of febuxostat for urate lowering in gout patients >/=65 years of ageBMC Geriatr2012121122436129
PubMed Web of Science ®Google Scholar
BeckerMASchumacherHRJrWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
PubMed Web of Science ®Google Scholar
ChohanSBeckerMAMacDonaldPAChefoSJacksonRLWomen with gout: efficacy and safety of urate-lowering with febuxostat and allopurinolArthritis Care Res (Hoboken)201264225626122052584
PubMed Web of Science ®Google Scholar
Garcia-ValladaresIKhanTEspinozaLREfficacy and safety of febuxostat in patients with hyperuricemia and goutTher Adv Musculoskelet Dis20113524525322870483
PubMedGoogle Scholar
GallinJIPrinciples and Practice of Clinical ResearchSan Diego, CAAcademic Press2002
Google Scholar
HummelJMcKendrickSBrindleyCFrenchRExploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterionPharm Stat200981384918386766
PubMed Web of Science ®Google Scholar
SmithBPVandenhendeFRDeSanteKAConfidence interval criteria for assessment of dose proportionalityPharm Res200017101278128311145235
PubMed Web of Science ®Google Scholar
KhosravanRGrabowskiBAWuJTJoseph-RidgeNVernilletLPharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjectsClin Pharmacokinet200645882184116884320
PubMed Web of Science ®Google Scholar
WyngaardenJBAllopurinol and xanthine nephropathyN Engl J Med197028373713725468407
PubMed Web of Science ®Google Scholar
BandPRSilverbergDSHendersonJFXanthine nephropathy in a patient with lymphosarcoma treated with allopurinolN Engl J Med197028373543575468406
PubMed Web of Science ®Google Scholar
GomezGAStutzmanLChuTMXanthine nephropathy during chemotherapy in deficiency of hypoxanthine-guanine phosphoribosyltransferaseArch Intern Med1978138610171019348139
PubMedGoogle Scholar
LaRosaCMcMullenLBakdashSAcute renal failure from xanthine nephropathy during management of acute leukemiaPediatr Nephrol200722113213517039332
PubMed Web of Science ®Google Scholar
TurnheimKKrivanekPOberbauerRPharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjectsBr J Clin Pharmacol199948450150910583019
PubMed Web of Science ®Google Scholar
GoldfingerSKlinenbergJRSeegmillerJEThe renal excretion of oxypurinesJ Clin Invest19654462362814278178
PubMed Web of Science ®Google Scholar
KhosravanRGrabowskiBWuJTJoseph-RidgeNVernilletLEffect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsBr J Clin Pharmacol200865335536317953718
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date